Product Line Growth:
Pharma Direct expanded rapidly, rising 41% in 2025 and 82% year over year to $52.2M in Q1 2026, while subscriptions grew 16% year over year in Q1 2026. New offerings such as Employer Direct and GoodRx Companion indicate continued build‑out of recurring and manufacturer‑aligned products.
Strategic Partnerships:
Manufacturer‑sponsored pricing programs and expanded partnerships underpinned Pharma Direct’s surge, including GLP‑1 launches and broader retail coverage. The company also reported tripling its retail e‑commerce footprint and an 83% quarter‑over‑quarter jump in Rx Marketplace order volume tied to new partnerships.
Strong Market Position & Advantage:
The platform is widely regarded as a leader in U.S. prescription savings, with acceptance at 70,000+ pharmacies and usage by nearly 30 million consumers and over one million healthcare professionals annually. This scale and reach reinforce its competitive position even as the business mix shifts.
